Allogeneic iC9-C7R-expressing Anti-CD30 CAR Epstein-Barr Virus-Specific T Lymphocytes

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of allogeneic human Epstein-Barr virus (EBV)-specific T-lymphocytes (EBVSTs) that have been genetically modified to express a chimeric antigen receptor (CAR) recognizing the tumor-associated antigen (TAA) cluster of differentiation 30 (CD30), the constitutively active interleukin 7 (IL-7) receptor (C7R; IL-7R), and the suicide gene inducible caspase 9 (iCasp9; iC9), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic iC9-C7R-expressing anti-CD30 CAR-EBVSTs specifically recognize and bind to CD30-expressing EBV-infected tumor cells, resulting in tumor cell lysis. C7R triggers IL-7-mediated signaling that promotes T-cell proliferation, survival, and anti-tumor activity. The iC9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered allogeneic C7R-expressing anti-CD30 CAR EBVSTs lead to unacceptable side effects, a homodimerizer can be administered, such as rimiducid, which binds to the FKBP12-F36V drug-binding domain, activates caspase 9 and results in apoptosis of the administered cells. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. EBV, a ubiquitous human herpes virus, is associated with various malignancies.

**Synonyms:** - Allogeneic C7R-expressing Anti-CD30 CAR EBVST Cells - Allogeneic iC9-C7R Anti-CD30 CAR-expressing EBVST Cells - Allogeneic iC9-C7R-expressing Anti-CD30 CAR-EBVSTs - C7R-expressing Anti-CD30 CAR Epstein-Barr Virus-Specific T Lymphocytes